T he weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a ...

About 30 million people suffer from sleep apnea in the US, Troxel told Fox News Digital. The agency said that along with the drug, a reduced-calorie diet and increased physical activity should ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The Food and Drug Administration has approved Zepbound to treat obstructive sleep apnea for people who are moderately or ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly drug initially developed as a treatment for ...

Zepbound is the first medication approved to treat people with obstructive sleep apnea, said Sailly Seymor, director of FDA's ...

This weight-loss drug, designed for obese patients, significantly reduces breathing disruptions and offers a new treatment ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.